- Galderma portfolio expands to offer a fast onset and long-acting alpha-2 adrenergic receptor agonist - Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today ...
For more information about this new treatment, visit www.mirvaso.com. Important Safety Information - Mirvaso® Gel Indication: Mirvaso ® (brimonidine) Topical Gel, 0.33%* is an alpha adrenergic agonist ...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing of brimonidine tartrate 3 mg/g topical gel (Mirvaso, Galderma) for the symptomatic ...
LAUSANNE, Switzerland, Sept. 11, 2017 /PRNewswire/ -- Today, the results of a study evaluating the combined use of topical rosacea treatments ivermectin 1% cream and brimonidine 0.33% gel were ...
The US Food and Drug Administration (FDA) has approved brimonidine topical gel 0.33% (Mirvaso, Galderma Laboratories) for facial redness resulting from rosacea in adults aged 18 years or older, the ...
Set Daily Express as a 'Preferred Source' to get quicker access to the news you value.
FORT WORTH, Texas--(BUSINESS WIRE)--Galderma Laboratories, L.P., a global leader focused on medical treatment options in dermatology and skin health and the maker of Cetaphil®, today announced the ...
If you experience persistent facial redness, blushing, acne-like breakouts, visible blood vessels and or burning, itching or stinging on your face(1), it may be a chronic inflammatory skin condition ...
Most people associate rosacea with flushed skin and visible blood vessels, but this chronic inflammatory condition can affect the skin in many ways. In fact, there are different subtypes of rosacea, ...
Please provide your email address to receive an email when new articles are posted on . The National Rosacea Society has released an updated version of its popular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results